9 months ago
India's Pharma Sector Shifts to Innovation
India's medicine-making industry is changing.
Instead of just making copies of existing medicines (generics), it's focusing on creating new and advanced medicines.
The government is helping by making rules easier and investing in research.
Experts say India needs to do this to stay important in the world's medicine market.
They are focusing on special types of medicines like biosimilars, peptides, and advanced treatments.
This change is happening at a big event called CPHI & PMEC India.
India's pharmaceutical sector is shifting from generics to an innovation-driven ecosystem.
Government and CDSCO reforms are accelerating this transition with streamlined approvals and reduced regulatory layers.
R&D projects worth Rs 5,000 crore have been recommended to support this shift.
India aims to become an innovation-led pharma nation within the next five years.
Experts emphasize the need for value-driven innovation in areas like peptides, complex generics, biosimilars, and advanced therapies.
- Who
- India's pharmaceutical sector, government, CDSCO, Pharmexcil, Namit Joshi
- What
- Shift from generics to innovation-driven ecosystem
- Where
- India
- When
- Ongoing transition, future vision for next 5 years
- Why
- To remain competitive in the global pharmaceutical landscape and become an innovation-led pharma nation
Key facts
- Sector Shift
- From generics to innovation-driven ecosystem
- Key Areas
- Biosimilars, peptides, complex generics, next-gen biologics
- Government Reforms
- Streamlined approvals, reduced regulatory layers, decriminalisation of non-serious offences
- R&D Investment
- Rs 5,000 crore recommended for R&D projects
- Future Vision
- India aims to become an innovation-led pharma nation in 5 years
- Global Landscape
- India must evolve beyond generics to remain the pharmacy of the world
- Value-Driven Innovation
- Focus on peptides, complex generics, biosimilars, biologics, targeted drug delivery, cell and gene therapies
- Event
- 18th edition of CPHI & PMEC India
Quotes
Dr. R Chandrashekar
Joint Drugs Controller, The Central Drugs Standard Control Organisation (CDSCO)
“This transition is being accelerated by government and CDSCO reforms such as streamlined approvals, reduced regulatory layers, decriminalisation of non-serious offences, and the recommendation of R&D projects worth Rs 5,000 crore.”
thestatesman.com
Namit Joshi
Chairman, Pharmaceuticals Export Promotion Council of India (Pharmexcil)
“The global pharmaceutical landscape is shifting rapidly, and India must evolve beyond its traditional generics mindset to remain the pharmacy of the world.”
thestatesman.com
Sources
Related news
India, Brazil Agree to Double Trade by 2030
Maharashtra Orders Strict Compliance At Blood Centres After Inspections
India Tightens Sale Rules for Four CNS Drugs
India Requires Sterilisation Licence Numbers On Device Labels
UK TPO Gel Nail Phaseout Raises Indian Safety Questions
